Geremie Palombaro, DO
Ophthalmology · Johnson City, NYNPI 1760611016
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 129 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 21.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $553, 2.5 times the $219 reported in 2019.
Across 129 payments — averaging $19.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$535
- Oyster Point Pharma, Inc.$410
- Alcon$261
- AbbVie$238
- Novartis$188
- Bausch & Lomb Americas Inc.$162
- plus $675 from 11 others
What the payments were for
- Food & beverage$2,469100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 23 | $535 |
| Oyster Point Pharma, Inc. | 22 | $410 |
| Alcon | 18 | $261 |
| AbbVie(2 entities) | 14 | $238 |
| Novartis | 12 | $188 |
| Bausch & Lomb Americas Inc. | 8 | $162 |
| Kala Pharmaceuticals, Inc. | 7 | $137 |
| Mallinckrodt Hospital Products Inc. | 5 | $103 |
| Shire North American Group Inc | 4 | $87 |
| Tarsus Pharmaceuticals, Inc. | 3 | $79 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $63 |
| GSK | 1 | $49 |
| Sun Pharmaceutical Industries Inc. | 3 | $44 |
| Harrow Eye, LLC | 2 | $37 |
| Dompe US, Inc. | 2 | $34 |
| Organogenesis Inc. | 1 | $33 |
| NEW World Medical,inc. | 1 | $9 |
How this compares
$2,469 in reported general payments places this provider in the 60th percentile of 1,587 ophthalmology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 47 | $78,658 |
| XiidraLifitegrast | 41 | $69,275 |
| LumiganBimatoprost | 94 | $60,188 |
| Cyclosporine | 41 | $31,008 |
| MieboPerfluorohexyloctane/Pf | 20 | $14,925 |
| TyrvayaVarenicline Tartrate | 15 | $9,663 |
| VyzultaLatanoprostene Bunod | 14 | $8,973 |
| RocklatanNetarsudil Mesylat/Latanoprost | 17 | $6,743 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 35 | $6,233 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 20 | $4,636 |
| Timolol Maleate | 166 | $4,154 |
| Prednisolone Acetate | 90 | $3,123 |
| Travoprost | 13 | $2,962 |
| Latanoprost | 140 | $2,041 |
| Brimonidine Tartrate | 41 | $1,661 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $238 | $138,846141 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta | $162 | $93,17375 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $410 | $9,66315 claims |
| AlconSimbrinza | $261 | $4,63620 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,587 ophthalmology providers in New York.
Other ophthalmology in Johnson City
- David RubaltelliBrooklyn$8.9M
- Nathan RadcliffeNew York$2.1M
- Richard SpaideNew York$1.7M
- Eric DonnenfeldGarden City$1.4M
- Marguerite McDonaldOceanside$893K
- Joshua YoungNew York$814K
- David KleinmanRochester$730K
- Jonathan JonischGreat Neck$726K
- Joseph PanarelliNew York$541K
- Eric RosenbergNew York$434K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.